Article in The Journal of infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
15 authors.
Phillip ChanDepartment of Neurology, Yale University School of Medicine, New Haven, Connecticut, USA.ORCID 0000-0002-4071-4409
Carlo SacdalanSEARCH Research Foundation, Bangkok, Thailand.
Suteeraporn PinyakornMilitary HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, Maryland, USA.ORCID 0000-0003-3880-4381
Eugène KroonSEARCH Research Foundation, Bangkok, Thailand.
Donn ColbyMilitary HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, Maryland, USA.
Pathariya PromsenaSEARCH Research Foundation, Bangkok, Thailand.
Somchai SriplienchanSEARCH Research Foundation, Bangkok, Thailand.
Nittaya PhanuphakInstitute of HIV Research and Innovation (IHRI), Bangkok, Thailand.ORCID 0000-0002-0036-3165
Sandhya VasanMilitary HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, Maryland, USA.ORCID 0000-0002-6378-6288
Victor ValcourGlobal Brain Health Institute (GBHI), University of California, San Francisco, California, USA.
Robert PaulFaculty of Psychological Sciences, Missouri Institute of Mental Health, University of Missouri-St. Louis, St. Louis, Missouri, USA.
Magnus GisslénDepartment of Infectious Diseases, Sahlgrenska Academy, Institute of Biomedicine, University of Gothenburg, Gothenburg, Sweden.ORCID 0000-0002-2357-1020
Henrik ZetterbergDepartment of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden.ORCID 0000-0003-3930-4354
Lydie TrautmannMilitary HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, Maryland, USA.
Serena SpudichDepartment of Neurology, Yale University School of Medicine, New Haven, Connecticut, USA.
Funding
Impact of IL-15 immunotherapy on tissue-specific CD8 T cells to reduce the CNS HIV reservoir seeding and persistenceR01MH130197 · NIMH · OREGON HEALTH & SCIENCE UNIVERSITY · PI Lishomwa C Ndhlovu, Afamefuna Okoye · 2022 to 2026
$5.1M
Long-Term CNS Consequences of Treatment During Acute InfectionR01MH095613 · NIMH · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI SPUDICH, SERENA S, VALCOUR, VICTOR · 2011 to 2015
$3.1M
Critical Role of Cytotoxic T Cells in HIV NeuropathogenesisR01MH106466 · NIMH · OREGON HEALTH & SCIENCE UNIVERSITY · PI PICKER, LOUIS J., SPUDICH, SERENA S · 2016 to 2020
$2.8M
Therapeutic Interventions during Acute Infection to Address the CNS Reservoir forR01NS084911 · NINDS · YALE UNIVERSITY · PI ANANWORANICH, JINTANAT, SPUDICH, SERENA S · 2013 to 2017
$2.3M
Advancement of Military Medicine, Inc.National Institute of Health AAI21058-001-01000NIH HHS R01MH095613NIH HHS R01MH106466NIH HHS R01MH130197NIH HHS R01NS084911NIMH NIH HHS R01 MH095613NIMH NIH HHS R01 MH106466NIMH NIH HHS R01 MH130197NINDS NIH HHS R01 NS084911
6 · The paper itself
Abstract
backgroundThis study evaluates the degree of neuroaxonal injury during acute HIV infection (AHI) in neuroasymptomatic individuals and the neuroprotective effect of antiretroviral therapy (ART) initiated during AHI, by measuring neurofilament light (NFL), glial fibrillary acidic protein (GFAP) and soluble triggering receptor expressed on myeloid cells 2 (sTREM2) in cerebrospinal fluid (CSF) samples collected during pre-ART AHI and at post-ART visits up to 5 years.
methodsRV254 cohort participants (99% male, median age 27 years) were enrolled during Fiebig I-V AHI. A subset completed optional lumbar punctures during pre-ART AHI (week 0, n = 136) and/or at post-ART visits with HIV suppression (weeks 24, 48, 96; and 240, n = 201). RV254 CSF NFL measurements were compared to those of 44 people without HIV (PWoH), both adjusted to a sampling age of 30, and to age-based upper normal limits (UNL).
resultsRV254 participants demonstrated higher CSF NFL than PWoH at pre-ART AHI (P < .001), and post-ART weeks 24 (P < .001) and 48 or later (week 48+, P = .003). CSF NFL was elevated (ie, >UNL) in 15%, 8%, and 7% of RV254 participants at weeks 0, 24, and 48 + respectively, versus 2% among PWoH. During AHI, elevated CSF NFL was associated with later Fiebig stages (III-V) (P = .034), higher CSF HIV RNA (P = .012) and a smaller difference between HIV RNA in the plasma and CSF (P = .002). Additionally, CSF NFL increased with GFAP and sTREM2 during pre-ART AHI and post-ART visits (P < .050).
conclusionsCNS injury may occur during AHI. Additionally, early ART alone is likely insufficient to provide complete neuroprotection.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Neuroaxonal Injury in Acute HIV Infection and Following Immediate Antiretroviral Therapy. · full record | OpenQuestion